Deep genomic analysis of solid tumours
celldx™ is a tissue based comprehensive molecular profiling of solid tumours with the aim to personalise therapy options. The results are generally available within 8 working days and, in addition to the genetic analysis, also provide information on the benefit of immune checkpoint inhibitors.
celldx™ provides advantages whenever ...
... there has to be a fast decision about a targeted therapy.
... an immunotherapy is an option for the patient.
FAQ
The turnaround time, after which the patient or his treating doctor will receive the results, is usually 8 working days from the day the laboratory receives the tissue sample. The test report contains all genomic highlights and lists the particular therapy options.
SNVs, INDELs, CNAs, Fusions, TMB, PD-L1, MSI, MMR, HRD (Homologous recombination deficiency).
Yes, celldx™ can provide information if a target alteration is present. Evaluation of therapies in the need of companion diagnostics across several cancer indications is available as well as clinical trial matching across all solid tumors.
celldx™ provides informed decisions if an immunotherapy is beneficial using genomic signatures like microsatellite instability (MSI), tumor mutational burden (TMB) and PD-L1 status via immunostaining.
Contact
Dr. Stefan Schuster
Managing Director Europe